Cellid Enters Phase 2a Clinical Trial for COVID-19 Preventive Vaccine
[Asia Economy Reporter Hyunseok Yoo] Cellid announced on the 25th that it will enter Phase 2a clinical trials for its self-developed COVID-19 preventive vaccine ‘AdCLD-CoV19’.
The Phase 2a clinical trial of ‘AdCLD-CoV19’, developed by Cellid, will be conducted on 120 healthy adult volunteers at a total of five institutions, including Korea University Guro Hospital, Korea University Ansan Hospital, Hallym University Gangnam Sacred Heart Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, and The Catholic University of Korea St. Vincent's Hospital. Subject enrollment is expected to begin sequentially as soon as IRB approvals are obtained from the clinical trial institutions.
The Phase 2a clinical trial of the COVID-19 preventive vaccine ‘AdCLD-CoV19’ will involve an 8-week follow-up period after subject administration to collect data on interim results.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Cellid stated, “We are currently conducting follow-up observations on the safety and immunogenicity of subjects from the previously conducted Phase 1 clinical trial,” adding, “Based on this, we expect to analyze the data and confirm interim results around April.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
